Dapagliflozin at Discharge on Hospital Heart Failure Readmission
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT04249778
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT04249778
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04249778. Randomized; double masking; primary purpose treatment. Start 2020-07-29 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-03-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin at Discharge on Hospital Heart Failure Readmission
- Condition
- Heart Failure
- Condition
- Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Emory University
Record details
- Record id
cardio:ct-nct04249778- Content hash
ca42047d42bced22a4a87e3fef4047b09cc42bd73baf9940f74b33ff040648da